Share this Page:
A recent study presented at the American Society for Clinical Oncology (ASCO) 2017 Genitourinary Cancer Symposium held in Orlando, Florida last month, reported a sustained response to PD-1/PD-L1 immunotherapy in patients with metastatic renal cell carcinoma (RCC) who had stopped treatment due to immune-related adverse events. This durable response lasted for more than 6 months and 42% of patients were able to remain off treatment. Also, it seems that the longer the duration of treatment prior to stopping, the more likely a durable response will be seen.
However, the researchers warn that the number of patients in this study is small, and, although the results are novel and compelling, further prospective studies are needed to further explore this finding.